A-967079
A-967079 is a chemical compound that acts as a selective antagonist of the cannabinoid receptor type 2 (CB2). It has been studied for its potential therapeutic applications in various medical conditions, particularly those involving inflammation and pain.
Chemical Properties[edit | edit source]
A-967079 is characterized by its selective binding affinity to the CB2 receptor, which is predominantly expressed in the immune system and peripheral tissues. This selectivity makes it a valuable tool for research into the physiological and pathological roles of CB2 receptors without affecting the cannabinoid receptor type 1 (CB1), which is primarily found in the central nervous system.
Mechanism of Action[edit | edit source]
As a CB2 receptor antagonist, A-967079 inhibits the action of endogenous cannabinoids that would normally activate the CB2 receptor. This inhibition can modulate immune responses and inflammatory processes, making it a potential candidate for treating conditions such as chronic pain, arthritis, and neuroinflammation.
Therapeutic Potential[edit | edit source]
Research into A-967079 has shown promise in several areas:
- **Pain Management**: By blocking CB2 receptors, A-967079 can reduce pain signaling pathways, offering a potential alternative to traditional pain medications.
- **Inflammatory Diseases**: The compound's ability to modulate immune responses makes it a candidate for treating inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease.
- **Neuroprotection**: There is ongoing research into the neuroprotective effects of CB2 antagonists, which could be beneficial in conditions such as multiple sclerosis and Alzheimer's disease.
Research and Development[edit | edit source]
A-967079 is still under investigation, and its safety and efficacy in humans have not yet been fully established. Preclinical studies have provided valuable insights, but further research is needed to determine its potential clinical applications.
See Also[edit | edit source]
- Cannabinoid receptor type 2
- Cannabinoid receptor type 1
- Endocannabinoid system
- Chronic pain
- Inflammation
- Neuroinflammation
References[edit | edit source]
External Links[edit | edit source]
-
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
